Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140259 | 0.86 | PPARA (0.42) | PPARAHRH3LTA4HPPARG | |
| SCHEMBL1603336 | 0.83 | S1PR1 (0.46) | KMT2AHRH3MEN1USP2ALDH1A1 | |
| SCHEMBL28135784 | 0.83 | NQO1 (0.38) | PPARAKMT2AHRH3LMNAPPARG | |
| SCHEMBL4738384 | 0.83 | CYP2C9 (0.46) | CYP4F2CYP4A11PPARAHRH3CA2 | |
| SCHEMBL17400983 | 0.82 | NQO1 (0.43) | PPARAKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL2141621 | 0.81 | CYP4F2 (0.55) | CYP4F2CYP4A11PPARAMAPK1PPARG | |
| SCHEMBL17400969 | 0.80 | NQO1 (0.61) | ALDH1A1SMN1; SMN2CA2LTA4H | |
| SCHEMBL1240940 | 0.80 | NQO1 (0.61) | CYP4F2CYP4A11PPARAKMT2AHRH3 | |
| SCHEMBL7362624 | 0.79 | NQO1 (0.40) | PPARAKMT2AMEN1MAPK1PPARG | |
| SCHEMBL8047274 | 0.79 | ACACB (0.52) | CYP4F2CYP4A11PPARAKMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380579-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| CN-106565674-B | Octahydrocyclopenta [ c ] pyrrole derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-02-05 | — | — | CN | disclosed |
| WO-2020078933-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND/OR SMARCA4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-04-23 | — | — | WO | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8476265-B2 | Compounds-801 | ASTRAZENECA AB (SE) | 2013-07-02 | — | — | US | disclosed |
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CYP4F2 69/4885CYP4A11 37/4885PPARA 239/4885 |
| US-20210380579-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4 | SMARCC1, SMARCA4, SMARCA1 | CYP4F2 4406/4885CYP4A11 1963/4885PPARA 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.